Cargando…

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pittock, Sean J, Fujihara, Kazuo, Palace, Jacqueline, Berthele, Achim, Kim, Ho Jin, Oreja-Guevara, Celia, Nakashima, Ichiro, Levy, Michael, Shang, Shulian, Yountz, Marcus, Miller, Larisa, Armstrong, Róisín, Wingerchuk, Dean M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894682/ https://www.ncbi.nlm.nih.gov/pubmed/34498507 http://dx.doi.org/10.1177/13524585211038291

Ejemplares similares

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
por: Berthele, Achim, et al.
Publicado: (2023)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
por: Wingerchuk, Dean M., et al.
Publicado: (2022)

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
por: Namatame, Chihiro, et al.
Publicado: (2021)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases
por: Saab, Georges, et al.
Publicado: (2022)

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses
por: Howard, James F., et al.
Publicado: (2021)

Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan
por: Nakashima, Ichiro, et al.
Publicado: (2023)

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study
por: Nowak, Richard J., et al.
Publicado: (2020)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
por: Hor, Jyh Yung, et al.
Publicado: (2020)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews
por: Capobianco, Marco, et al.
Publicado: (2023)

Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?
por: Fujihara, Kazuo, et al.
Publicado: (2014)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

The patient journey with NMOSD: From initial diagnosis to chronic condition
por: Delgado-Garcia, Guillermo, et al.
Publicado: (2022)

Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis
por: Messina, Silvia, et al.
Publicado: (2021)

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
por: Shi, Mingchao, et al.
Publicado: (2022)

Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome
por: McCombe, Jennifer A., et al.
Publicado: (2023)

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
por: Kleiter, Ingo, et al.
Publicado: (2018)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

Lupus and NMOSD: The Blending of Humoral Autoimmunity
por: Ochi, Maria Goretti S., et al.
Publicado: (2020)

Epidemiology of Pediatric NMOSD in Germany and Austria
por: Lechner, Christian, et al.
Publicado: (2020)

Contemporary management challenges in seropositive NMOSD
por: Costello, Fiona, et al.
Publicado: (2022)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

Plasmapheresis for NMOSD: Not a Rescue Therapy Anymore!?
por: Bhatia, Rohit, et al.
Publicado: (2019)

Plegia to walking: AHSCBMT in severe NMOSD relapse
por: Carlisle, Nicola, et al.
Publicado: (2020)

Therapy challenges for NMOSD in a patient with HIV
por: Engels, Daniel, et al.
Publicado: (2023)

Patterns of cortical grey matter thickness reduction in multiple sclerosis
por: Fujimori, Juichi, et al.
Publicado: (2021)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8uvvk81soc46ijspp0br4pn820